Bristol-Myers Squibb Co (BMY) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA trimmed its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 4.7% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 28,204 shares of the biopharmaceutical company’s stock after selling 1,386 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Bristol-Myers Squibb were worth $1,346,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Rockland Trust Co. lifted its position in Bristol-Myers Squibb by 30.7% during the first quarter. Rockland Trust Co. now owns 103,702 shares of the biopharmaceutical company’s stock valued at $4,948,000 after purchasing an additional 24,355 shares during the last quarter. Neville Rodie & Shaw Inc. lifted its position in Bristol-Myers Squibb by 0.3% during the first quarter. Neville Rodie & Shaw Inc. now owns 85,255 shares of the biopharmaceutical company’s stock valued at $4,067,000 after purchasing an additional 275 shares during the last quarter. Montecito Bank & Trust lifted its position in Bristol-Myers Squibb by 10.6% during the first quarter. Montecito Bank & Trust now owns 20,925 shares of the biopharmaceutical company’s stock valued at $998,000 after purchasing an additional 2,000 shares during the last quarter. Bridge Creek Capital Management LLC lifted its position in Bristol-Myers Squibb by 8.7% during the first quarter. Bridge Creek Capital Management LLC now owns 6,230 shares of the biopharmaceutical company’s stock valued at $297,000 after purchasing an additional 500 shares during the last quarter. Finally, Underhill Investment Management LLC bought a new position in Bristol-Myers Squibb during the first quarter valued at $365,000. 74.28% of the stock is owned by institutional investors.

Several equities analysts have commented on BMY shares. BMO Capital Markets reiterated a “buy” rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a research report on Thursday, January 3rd. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Thursday, January 3rd. ValuEngine lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Friday, January 4th. Edward Jones lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. Finally, Societe Generale upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “buy” rating in a research report on Tuesday, January 15th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $59.14.

Bristol-Myers Squibb stock opened at $45.52 on Monday. The stock has a market capitalization of $74.38 billion, a PE ratio of 11.44, a PEG ratio of 2.34 and a beta of 0.79. Bristol-Myers Squibb Co has a 12-month low of $44.30 and a 12-month high of $63.69. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.61 and a quick ratio of 1.50.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.09. The company had revenue of $5.97 billion for the quarter, compared to the consensus estimate of $5.95 billion. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. The firm’s revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.68 EPS. Research analysts forecast that Bristol-Myers Squibb Co will post 4.16 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 3.60%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Co (BMY) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/04/22/bristol-myers-squibb-co-bmy-shares-sold-by-loring-wolcott-coolidge-fiduciary-advisors-llp-ma.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: What is diluted earnings per share (Diluted EPS)?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.